| Serial Number | 88148638 |
| Word Mark | FIBRISTAL |
| Filing Date | Tuesday, October 9, 2018 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, October 10, 2022 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, July 9, 2019 |
| Description of Mark | The mark consists of the word "FIBRISTAL" in lower case letters, with portions of three leaves extending generally upwards from the top of the letter "B". |
| Goods and Services | Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system (CNS) disorders, neurological disorders, neurodegenerative disorders, and depression; pharmaceutical preparations, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations; sterile antibiotic and anti-inflammatory ointments; ocular wetting solutions, namely, eye drops, artificial tears and pharmaceutical gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and medicated creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, medicated toners, medicated moisturizers, medicated rejuvenators, medicated rehydrating creams, and medicated lotions for the face and body |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, October 19, 2018 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Allergan Sales, LLC |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Irvine, CA 92612 |
| Party Name | Allergan Sales, LLC |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | Madison, NJ 07940 |
| Event Date | Event Description |
| Tuesday, October 11, 2022 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, October 10, 2022 | ABANDONMENT - NO USE STATEMENT FILED |
| Wednesday, March 16, 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, March 15, 2022 | SOU EXTENSION 5 GRANTED |
| Thursday, March 3, 2022 | SOU EXTENSION 5 FILED |
| Monday, March 14, 2022 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Thursday, March 3, 2022 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, August 10, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, August 6, 2021 | SOU EXTENSION 4 GRANTED |
| Friday, August 6, 2021 | SOU EXTENSION 4 FILED |
| Friday, August 6, 2021 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, March 2, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, February 26, 2021 | SOU EXTENSION 3 GRANTED |
| Friday, February 26, 2021 | SOU EXTENSION 3 FILED |
| Friday, February 26, 2021 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, August 25, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, August 21, 2020 | SOU EXTENSION 2 GRANTED |
| Friday, August 21, 2020 | SOU EXTENSION 2 FILED |
| Friday, August 21, 2020 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, March 3, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, February 28, 2020 | SOU EXTENSION 1 GRANTED |
| Friday, February 28, 2020 | SOU EXTENSION 1 FILED |
| Friday, February 28, 2020 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, September 3, 2019 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, July 9, 2019 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, July 9, 2019 | PUBLISHED FOR OPPOSITION |
| Wednesday, June 19, 2019 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Monday, June 3, 2019 | ASSIGNED TO LIE |
| Monday, May 20, 2019 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, November 14, 2018 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Wednesday, November 14, 2018 | LETTER OF SUSPENSION E-MAILED |
| Wednesday, November 14, 2018 | SUSPENSION LETTER WRITTEN |
| Tuesday, November 13, 2018 | ASSIGNED TO EXAMINER |
| Saturday, October 20, 2018 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Friday, October 19, 2018 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, October 12, 2018 | NEW APPLICATION ENTERED |